Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015841
Chunk: 12

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 12
---
's power to fight disease, with the aim of forming a joint venture for the co-development and commercialization of thermostable mRNA-based vaccines utilizing each company's respective proprietary technologies. In parallel with such ongoing negotiations, Medicus and HelixNano have formalized their mutual intent to collaborate on the research, development and production of a batch of clinical-grade mRNA vaccine-loaded MNAs, which are intended for use in a Phase 1 clinical bridging study to compare the safety and preliminary efficacy of intramuscular injection vs. intradermal MNA delivery of HelixNano's vaccine candidate HN-0001, through the proposed joint venture.

On August 21, 2025, the Company announced that the FDA accepted the Company’s Type C Meeting request to formally discuss the D-MNA product development and gain further alignment on the clinical pathway. In September 2025, the FDA provided written responses to the Company’s queries, and agreed that the Company can rely on the 505(b)(2) regulatory pathway to treat BCC using D-MNA.

On September 8, 2025, the Company announced that its SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin, has commenced patient recruitment in Cleveland clinic Abu Dhabi.

On September 12, 2025, the Company announced that James Quinlan, Chief Financial Officer of the Company, will be taking a medical leave of absence from the Company commencing on such date and that Carolyn Bonner was appointed as acting Chief Financial Officer of the Company in addition to maintaining her current role as President of the Company.

On September 17, 2025, the Company entered into a securities purchase agreement (the "Purchase Agreement") with Yorkville (as defined herein) in connection with the issuance and sale by the Company of a debenture (the "Debenture") in the principal amount of $8.0 million. The Company used a portion of the proceeds from the issuance of the Debenture to fully satisfy and discharge the approximately $1.7 million remaining outstanding balance of the $5.0 million aggregate principal amount of debentures that Yorkville purchased from the Company in May and June 2025 pursuant to a purchase agreement dated May 2, 2025. The Debenture is guaranteed by each of the Company's subsidiaries pursuant to a global guaranty agreement (the "Guaranty"). Interest will accrue on the outstanding principal amount of the Debenture at an